Issue Information.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 327, doi. 10.1002/cncy.22876
- Publication type:
- Article
Works matching IS 1934662X AND DT 2024 AND VI 132 AND IP 6
Results: 8
1
2
Reimagining the future of cancer clinical trials: Reformers are eyeing multiple ways to make drug trials more efficient, patient‐centered, and likely to succeed.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 331, doi. 10.1002/cncy.22837
- By:
- Publication type:
- Article
3
Papillae, psammoma bodies, and/or many nuclear pseudoinclusions are helpful criteria but should not be required for a definitive cytologic diagnosis of papillary thyroid carcinoma: An institutional experience of 207 cases with surgical follow up.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 348, doi. 10.1002/cncy.22817
- By:
- Publication type:
- Article
4
Spotlight: Rising stars in cytology.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 333, doi. 10.1002/cncy.22813
- By:
- Publication type:
- Article
5
Challenging the concept of "risk of malignancy" in cytology.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 335, doi. 10.1002/cncy.22787
- By:
- Publication type:
- Article
6
Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 370, doi. 10.1002/cncy.22811
- By:
- Publication type:
- Article
7
Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1‐altered thyroid lesions on FNA: A multipractice experience.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 359, doi. 10.1002/cncy.22805
- By:
- Publication type:
- Article
8
Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions.
- Published in:
- Cancer Cytopathology, 2024, v. 132, n. 6, p. 340, doi. 10.1002/cncy.22802
- By:
- Publication type:
- Article